HomeCYCCP • NASDAQ
Cyclacel Pharmaceuticals Inc Conv. Pref. Shrs
$18.20
Mar 28, 6:58:00 AM GMT-4 · USD · NASDAQ · Disclaimer
StockUS listed securityUS headquartered
Previous close
$17.98
Year range
$5.25 - $22.20
Market cap
2.62M USD
Avg Volume
1.05K
P/E ratio
-
Dividend yield
-
In the news
Financials
Income Statement
Revenue
Net income
(USD)Dec 2023Y/Y change
Revenue
31.00K
Operating expense
5.39M-39.05%
Net income
-5.27M28.95%
Net profit margin
-17.00K
Earnings per share
-6.2330.78%
EBITDA
-5.35M39.43%
Effective tax rate
7.41%
Total assets
Total liabilities
(USD)Dec 2023Y/Y change
Cash and short-term investments
3.38M-81.59%
Total assets
8.80M-68.61%
Total liabilities
8.20M-32.31%
Total equity
607.00K
Shares outstanding
854.03K
Price to book
25.32
Return on assets
-125.81%
Return on capital
-536.75%
Net change in cash
(USD)Dec 2023Y/Y change
Net income
-5.27M28.95%
Cash from operations
Cash from investing
Cash from financing
Net change in cash
Free cash flow
About
Cyclacel Pharmaceuticals Inc. is a biotechnology firm based in Berkeley Heights, New Jersey and Dundee, Scotland, developing cancer treatments. Cyclacel was founded in 1996 by David Lane, PhD. Wikipedia
Founded
Aug 13, 1996
Employees
12
Discover more
You may be interested in
This list is generated from recent searches, followed securities, and other activity. Learn more

All data and information is provided “as is” for personal informational purposes only, and is not intended to be financial advice nor is it for trading purposes or investment, tax, legal, accounting or other advice. Google is not an investment adviser nor is it a financial adviser and expresses no view, recommendation or opinion with respect to any of the companies included in this list or any securities issued by those companies. Please consult your broker or financial representative to verify pricing before executing any trades. Learn more
People also search for
Search
Clear search
Close search
Google apps
Main menu